Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists...

Details Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists... Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists...

2011-06-21

2011-06-21

Oh, Taylor Victor (Department: 1625)

Drug, bio-affecting and body treating compositions

Designated organic active ingredient containing

Having -c-, wherein x is chalcogen, bonded directly to...

C546S155000, C546S157000

Reexamination Certificate

active

07964615

ABSTRACT:
A compound of formula (I) or a pharmaceutically-acceptable salt, solvate or stereoisomer thereof wherein R1is a group chosen from —CH2OH and —NHC(O)H; R2is a hydrogen atom or R1together with R2form the group —NH—C(O)—CH═CH—, wherein the nitrogen atom is bound to the carbon atom in the phenyl ring holding R1and the carbon atom is bound to the carbon atom in the phenyl ring holding R2; R3is chosen from a hydrogen atom, a halogen atom and groups chosen from —SO—R5, —SO2—R5, —NH—CO—NH2, —CO—NH2, hydantoino, C1-4alkyl, C1-4alkoxy and —SO2NR5R6; R4is chosen from a hydrogen atom, a halogen atom and a C1-4alkyl group; R5is chosen from a C1-4alkyl group and a C3-8cycloalkyl group; R6is independently chosen from a hydrogen atom and a C1-4alkyl group; n, p and q are independently 0, 1, 2, 3 or 4; m and s are independently 0, 1, 2 or 3; and r is 0, 1 or 2 with the provisos that at least one of m and r is not 0, the sum n+m+p+q+r+s is 7, 8, 9, 10, 11, 12 or 13, and the sum q+r+s is 2, 3, 4, 5 or 6.

REFERENCES:
patent: 3678137 (1972-07-01), Pfeiffer et al.
patent: 3970677 (1976-07-01), Nishimura et al.
patent: 3975391 (1976-08-01), Nakagawa et al.
patent: 3994901 (1976-11-01), Nakagawa et al.
patent: 4022776 (1977-05-01), Nakagawa et al.
patent: 4022784 (1977-05-01), Nakagawa et al.
patent: 4026897 (1977-05-01), Nakagawa et al.
patent: 4068076 (1978-01-01), Nakagawa et al.
patent: 4145542 (1979-03-01), Nakagawa et al.
patent: 4753962 (1988-06-01), Ainsworth et al.
patent: 4997986 (1991-03-01), Mitchell et al.
patent: 5099068 (1992-03-01), Mitchell et al.
patent: 5109023 (1992-04-01), Mitchell et al.
patent: 5201308 (1993-04-01), Newhouse
patent: 5263475 (1993-11-01), Altermatt et al.
patent: 5283262 (1994-02-01), Mitchell et al.
patent: 5435301 (1995-07-01), Herold et al.
patent: 5507281 (1996-04-01), Kuhnel et al.
patent: 5617845 (1997-04-01), Poss et al.
patent: 5685294 (1997-11-01), Gupte et al.
patent: 6541669 (2003-04-01), Moran et al.
patent: 2002/0055651 (2002-05-01), Moran et al.
patent: 2003/0136405 (2003-07-01), Goede et al.
patent: 2003/0153597 (2003-08-01), Moran et al.
patent: 2004/0059116 (2004-03-01), Moran et al.
patent: 2004/0167167 (2004-08-01), Mammen et al.
patent: 2005/0043337 (2005-02-01), Rito et al.
patent: 2005/0159448 (2005-07-01), McKinnell et al.
patent: 2005/0192316 (2005-09-01), Moran et al.
patent: 2005/0215590 (2005-09-01), Brown et al.
patent: 2005/0272769 (2005-12-01), Linsell
patent: 2006/0019991 (2006-01-01), McKinnell et al.
patent: 2006/0035931 (2006-02-01), Chao et al.
patent: 2006/0081246 (2006-04-01), Goede et al.
patent: 2006/0178410 (2006-08-01), Moran et al.
patent: 2007/0197536 (2007-08-01), Dal Piaz et al.
patent: 2009/0082378 (2009-03-01), Puig Duran et al.
patent: 2010/0093681 (2010-04-01), Puig Duran et al.
patent: 2010/0168161 (2010-07-01), Tanä et al.
patent: 2 236 272 (1973-02-01), None
patent: 2 310 140 (1974-09-01), None
patent: 2 461 861 (1975-08-01), None
patent: 4 239 402 (1994-05-01), None
patent: 0 069 715 (1983-01-01), None
patent: 0 147 719 (1985-07-01), None
patent: 0 166 294 (1986-01-01), None
patent: 0 286 242 (1988-10-01), None
patent: 0 317 206 (1989-05-01), None
patent: 0 424 790 (1991-05-01), None
patent: 0 505 321 (1992-09-01), None
patent: 0 674 533 (1995-10-01), None
patent: 1 078 629 (2001-02-01), None
patent: 1 235 787 (2002-09-01), None
patent: 1 577 291 (2005-09-01), None
patent: 2 232 306 (2005-05-01), None
patent: 1 200 886 (1970-08-01), None
patent: 1 247 370 (1971-09-01), None
patent: 1 458 251 (1976-12-01), None
patent: 1 468 156 (1977-03-01), None
patent: 2 041 763 (1980-09-01), None
patent: 2 140 800 (1984-12-01), None
patent: 2 160 863 (1986-01-01), None
patent: 2 165 159 (1986-04-01), None
patent: 2 242 134 (1991-09-01), None
patent: 51 149 282 (1976-12-01), None
patent: 59 093 051 (1984-05-01), None
patent: WO 91/02558 (1991-03-01), None
patent: WO 91/14468 (1991-10-01), None
patent: WO 92/00771 (1992-01-01), None
patent: WO 92/03175 (1992-03-01), None
patent: WO 92/04068 (1992-03-01), None
patent: WO 92/04928 (1992-04-01), None
patent: WO 92/09322 (1992-06-01), None
patent: WO 96/32150 (1996-10-01), None
patent: WO 97/00703 (1997-01-01), None
patent: WO 97/12687 (1997-04-01), None
patent: WO 98/09632 (1998-03-01), None
patent: WO 99/30703 (1999-06-01), None
patent: WO 99/64035 (1999-12-01), None
patent: WO 01/36375 (2001-05-01), None
patent: WO 01/42193 (2001-06-01), None
patent: WO 02/066422 (2002-08-01), None
patent: WO 02/070490 (2002-09-01), None
patent: WO 02/092606 (2002-11-01), None
patent: WO 03/000325 (2003-01-01), None
patent: WO 03/042160 (2003-05-01), None
patent: WO 03/061742 (2003-07-01), None
patent: WO 03/072539 (2003-09-01), None
patent: WO 03/097613 (2003-11-01), None
patent: WO 03/099764 (2003-12-01), None
patent: WO 2004/011416 (2004-02-01), None
patent: WO 2004/016578 (2004-02-01), None
patent: WO 2004/058729 (2004-07-01), None
patent: WO 2004/089892 (2004-10-01), None
patent: WO 2004/106279 (2004-12-01), None
patent: WO 2005/030678 (2005-04-01), None
patent: WO 2005/049581 (2005-06-01), None
patent: WO 2005/121065 (2005-12-01), None
patent: WO 2005/123692 (2005-12-01), None
patent: WO 2005/123693 (2005-12-01), None
patent: WO 2006/023457 (2006-03-01), None
patent: WO 2006/051375 (2006-05-01), None
patent: WO 2007/124898 (2007-11-01), None
patent: WO 2008/046598 (2008-04-01), None
patent: WO 2008/095720 (2008-08-01), None
patent: WO 2009/068177 (2009-06-01), None
patent: WO 2009/106351 (2009-09-01), None
Ismail, FMD. “Important fluorinated drugs in experimental and clinical use,”Journal of Fluorine Chemistry118:27-33 (2002).
Smart, BE. “Fluorine substituent effects (on bioactivity),”Journal of Fluorine Chemistry109:3-11 (2001).
International Search Report mailed Sep. 12, 2006, for International Application No. PCT/EP2006/004680 (WO 2006/122788 A1).
Caplus English Abstract of DE 2 236 272, Accession No. 1973:405128.
Caplus English Abstract of DE 2 310 140, Accession No. 1975:31115.
Caplus English Abstract of JP 51 149 282, Accession No. 1977:468184.
Caplus English Abstract of JP 59 093 051, Accession No. 1985:45790.
Caplus English Abstract of journal article by Meglio, P. et al. Accession No. 1980:426036.
Deyrup, M.D. et al. “Structure-affinity profile of 8-hydroxycarbostyril-based agonists that dissociate slowly from the β2-adrenoceptor,”Naunyn-Schmiedeberg's Archives of Pharmacology, 359: 168-177(1999).
Meglio, P. et al. “Synthesis and pharmacological study of orciprenaline and salbutamol derivatives,”Farmaco, Edizione Scientifica, 35(3): 203-230 (1980).
Yoshizaki, S. et al. “Sympathomimetic Amines having a 3,4-Dihydrocarbostyril Nucleus,”Chemical and Pharmaceutical Bulletin, 26(5): 1611-1614 (1978).
Coleman, R.A. et al. “Novel and Versatile Superfusion System,”Journal of Pharmacological Methods, 21: 71-86 (1989).
Curran, P.K. et al. “Endogenous β3-But Not β1-Adrenergic Receptors Are Resistant to Agonist-Mediated Regulation in Human SK-N-MC Neurotumor Cells,”Cell. Signal., 8(5): 355-364 (1996).
Furuie, H. et al. “Suppressive effect of novel phosphodiesterase4 (PDE4) inhibitor ONO-6126 on TNF-α release was increased after repeated oral administration in healthy Japanese subjects,”Eur. Resp. Journal, 22(Supp. 45):Abstract 2557 (2003).
Hart, D.J. “A Synthesis of (±)-Gephyrotoxin,”Journal of Organic Chemistry, 46:3576-3578 (1981).
Hart, D.J. et al. “Total Syntheses ofdl-Gephyrotoxin anddl-Dihydrogephyrotoxin,”J. American Chem. Society, 105(5): 1255-1263 (1983).
Hett, R. et al. “Enantioselective Synthesis of Salmeterol via Asymmetric Borane Reduction,”Tetrahedron Letters, 35(50): 9375-9378 (1994).
Hett, R. et al. “Large-Scale Synthesis of Enantio- and Diastereomerically Pure (R,R)-Formoterol,”Organic Process Research&Development, 2(2): 96-99 (1998).
Kaiser, C. et al.

Affiliated with

Also associated with

Rating

Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists... does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Derivatives of 4-(2-amino-1-hydroxyethyl)phenol as agonists... will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-2730206